Skip to main content

Table 1 Main characteristics of randomized controlled trials (RCT) on the use of GnRH in luteal phase

From: Administration of single-dose GnRH agonist in the luteal phase in ICSI cycles: a meta-analysis

Trial

Randomization

Protocol stimulation

Luteal Phase

Results

   

Study group

GnRH-a

Control group

Others medicines

(all patients)

 

Tesarik et al., 2006 [18]

Embryo transfer day

Computer generated list

Opaque envelopes

Blinding

GnRH-a long protocol/GnRH-ant multiple dose

+

r-FSH/HMG

+

r-HCG

n:150 GnRH-a long protocol)

n:150 GnRH-ant protocol

Single injection

Dose:0.1 mg/triptorelin

Day 6 after ICSI

n:150

(GnRHa-long protocol)

n:150

(Antagonist protocol)

Placebo

E2 valerate (4 mg)

+

Vaginal micronized progesterone(400 mg) +

r-HCG (single dose)

Improvement implantation/live birth rates

Ata et al., 2008 [24]

Embryo transfer day

Computer generated list

Opaque envelopes

Blinding

GnRH-a long protocol

+

r-FSH

+

HCG

n:285

Single injection

Dose:0.1 mg/triptorelin

Day 6 after ICSI

n:285

Placebo

Vaginal progesterone gel/90 mg

No differences

Isik et al., 2009 [15]

Embryo transfer day

Computer generated list

Blinding

GnRH-ant multiple dose +

r-FSH/HMG

+

hCG/r-hCG

n:74

Single injection

Dose:0.5 mg/leuprolide

Day 6 after ICSI

n:80

No placebo

Vaginal micronized progesterone(600 mg) +

HCG(single dose)

Improvement implantation/clinical pregnancy rates

Razieh et al., 2009 [16]

Drawing piece of paper from a bag

GnRH-a long protocol

+

r-FSH

+

HCG

n:90

Single injection

Dose:0.1 mg/triptorelin

Day 5/6 after ICSI

n:90

Placebo

Vaginal micronized progesterone(800 mg)

Improvement implantation/clinical pregnancy rates

Ata and Urman, 2010 [23]

Embryo transfer day

Computer generated list

Opaque envelopes

Blinding

GnRH-ant multiple dose +

r-FSH/HMG

+

r-HCG

n:38

Single injection

Dose:0.1 mg/triptorelin

Day 6 after ICSI

n:52

Placebo

Vaginal progesterone gel/90 mg

Lower Implantation/ongoing pregnancy rates